[HTML] springer.comFull View

[HTML][HTML] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - Springer
Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
被引用次数：115 相关文章

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - europepmc.org
BACKGROUND: Prospective evidence is lacking regarding incremental benefits of long-
acting dual-versus mono-bronchodilation in improving symptoms and preventing short-term …

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - hero.epa.gov
BACKGROUND: Prospective evidence is lacking regarding incremental benefits of long-
acting dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
[HTML] biomedcentral.com

[HTML][HTML] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled …

F Maltais, L Bjermer, EM Kerwin… - Respiratory …, 2019 - respiratory-research.biomedcentral …
Prospective evidence is lacking regarding incremental benefits of long-acting dual-versus
mono-bronchodilation in improving symptoms and preventing short-term disease …

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - go.gale.com
Background Long-acting bronchodilators, including long-acting muscarinic antagonists
(LAMAs) and long-acting [beta] 2-agonists (LABAs), form the basis of maintenance therapy …

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - 2019 - pubmed.ncbi.nlm.nih.gov
Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
[PDF] academia.edu

[PDF][PDF] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - 2019 - academia.edu
Background: Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus monobronchodilation in improving symptoms and preventing short-term disease …
[HTML] nih.gov

[HTML][HTML] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - ncbi.nlm.nih.gov
Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
[PDF] biomedcentral.com

[PDF][PDF] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids …

F Maltais, L Bjermer, EM Kerwin, PW Jones… - 2019 - respiratory-research.biomedcentral …
Background: Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus monobronchodilation in improving symptoms and preventing short-term disease …